Payment overview · 2025
General Payments
$816.96
45 reported records · 10 companies
Healthcare provider profile · identity verified
Collin E. Ball
Podiatric Medicine & Surgery Service Providers|Podiatrist|Foot & Ankle Surgery · LONDON, KY · NPI 1619166378
Verified facts
What the public records show
CMS Open Payments records show Collin E. Ball received $816.96 in general payments during 2025 across 45 reported records.
ACUMED LLC accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuzyra, Qutenza.
Averitas Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QUTENZA as an associated drug or biological on 11743 records involving 7078 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Qutenza by this doctor in 2024.
Paratek Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUZYRA as an associated drug or biological on 24089 records involving 10216 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nuzyra by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ACUMED LLC | Unresolved — no canonical attribution shown | $162.80 | 19.9% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $157.95 | 19.3% | 11 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $153.63 | 18.8% | 13 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $144.57 | 17.7% | 9 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $91.85 | 11.2% | 4 | 2025 |
| Linvatec Corporation | Unresolved — no canonical attribution shown | $38.55 | 4.7% | 1 | 2025 |
| Sanara MedTech Inc. | Unresolved — no canonical attribution shown | $18.94 | 2.3% | 1 | 2025 |
| TREACE MEDICAL CONCEPTS, INC. | Unresolved — no canonical attribution shown | $16.73 | 2.0% | 1 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $16.17 | 2.0% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $15.77 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $816.96 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Acumed Normalized: acumed |
Device | ACUMED LLC | $162.80 | 3 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $157.95 | 11 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $153.63 | 13 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $91.85 | 4 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $44.42 | 5 | 2025 |
Source payment records
|
|||||
| ALLOGRAFT TISSUE Normalized: allograft tissue |
Device | Linvatec Corporation | $38.55 | 1 | 2025 |
Source payment records
|
|||||
| BIOBRACE 23MM Normalized: biobrace 23mm |
Device | Linvatec Corporation | $38.55 | 1 | 2025 |
Source payment records
|
|||||
| NEOSPAN Normalized: neospan |
Device | Linvatec Corporation | $38.55 | 1 | 2025 |
Source payment records
|
|||||
| QUANTUM Normalized: quantum |
Device | Linvatec Corporation | $38.55 | 1 | 2025 |
Source payment records
|
|||||
| REGRANEX Normalized: regranex |
Drug | Smith+Nephew, Inc. | $30.28 | 3 | 2025 |
Source payment records
|
|||||
| OASIS Normalized: oasis |
Device | Smith+Nephew, Inc. | $29.35 | 1 | 2025 |
Source payment records
|
|||||
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $25.01 | 1 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| STRAVIX PL Normalized: stravix pl |
Biological | Smith+Nephew, Inc. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| Iodosorb Ointment 40g USA Normalized: iodosorb ointment 40g usa |
Device | Smith+Nephew, Inc. | $19.64 | 2 | 2025 |
Source payment records
|
|||||
| CellerateRX Normalized: celleraterx |
Device | Sanara MedTech Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| LAPIPLASTY SYSTEM 1 Normalized: lapiplasty system 1 |
Device | TREACE MEDICAL CONCEPTS, INC. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| Exparel Normalized: exparel |
Drug | Pacira Pharmaceuticals Incorporated | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $15.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUZYRA nuzyra |
2025 | Nuzyra | 2024 | 26 | exact normalized | Medicare Part D |
| QUTENZA qutenza |
2025 | Qutenza | 2024 | 38 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Averitas Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | QUTENZA open payments reported associated product |
CMS Open Payments — General Payments 11743 supporting records · 7078 recipient NPIs · example record 1248543069 |
Qutenza · 2024 Exact normalized brand match · 1 Part D row |
38 | 18 |
| Paratek Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | NUZYRA open payments reported associated product |
CMS Open Payments — General Payments 24089 supporting records · 10216 recipient NPIs · example record 1181734338 |
Nuzyra · 2024 Exact normalized brand match · 1 Part D row |
26 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 610 | 68 |
| Pregabalin | Pregabalin | 286 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 150 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 100 | 55 |
| Ammonium Lactate | Ammonium Lactate | 82 | 43 |
| Clindamycin Hcl | Clindamycin Hcl | 68 | 46 |
| Ibuprofen | Ibuprofen | 68 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 14 |
| Clotrimazole | Clotrimazole | 54 | 29 |
| Prednisone | Prednisone | 43 | 38 |
| Neomycin Sulfate | Neomycin Sulfate | 41 | 19 |
| Alendronate Sodium | Alendronate Sodium | 39 | 13 |
| Qutenza | Capsaicin/Skin Cleanser | 38 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 26 |
| Vancomycin Hcl | Vancomycin Hcl | 36 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 23 |
| Cephalexin | Cephalexin | 33 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 12 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 28 | 19 |
| Itraconazole | Itraconazole | 26 | 11 |
| Nuzyra | Omadacycline Tosylate | 26 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | 20 |
| Tramadol Hcl | Tramadol Hcl | 25 | 11 |
| Levofloxacin | Levofloxacin | 24 | 15 |
| Nabumetone | Nabumetone | 23 | suppressed |
| Tobramycin Sulfate | Tobramycin Sulfate | 23 | 12 |
| Ertapenem | Ertapenem Sodium | 22 | suppressed |
| Linezolid | Linezolid | 20 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 13 |
| Voriconazole | Voriconazole | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Meloxicam | Meloxicam | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $816.96 · 45 records | ACUMED LLC | ACTIV.A.C., ALLOGRAFT TISSUE, Acumed, BIOBRACE 23MM, COLLAGENASE SANTYL, CellerateRX, Exparel, GRAFIX PL, Iodosorb Ointment 40g USA, JOURNAVX, LAPIPLASTY SYSTEM 1, NEOSPAN, NUZYRA, OASIS, QUANTUM, QUTENZA, REGRANEX, STRAVIX, STRAVIX PL | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuzyra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Averitas Pharma Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error